Study of Oral MRT-2359 With Apalutamide in Prostate Cancer

Summary

This Phase 2, open-label, multicenter study is conducted in patients with castration-resistant prostate cancer. Patients in this study receive MRT-2359, an investigational oral medicine, in combination with apalutamide, an oral medicine used to treat prostate cancer. The main purpose of the study is to assess whether this treatment combination can lower prostate-specific antigen (PSA) The study will also evaluate the safety and tolerability of the treatment combination and assess additional measures of anti-tumor activity.

Eligibility

Inclusion Criteria:

* Age \> 18 years
* A predicted life expectancy of ≥ 3 months and an ECOG performance status ≤ 1
* Have histologically or cytologically confirmed castration-resistant adenocarcinoma of the prostate without small cell histology and with androgen receptor (AR) mutations
* Have not had prior treatment with more than 1 prior taxane-based chemotherapy regimen for castration-resistant prostate cancer
* Have no prior treatment with an AR degrader, opevesostat, or similar therapy
* Has ongoing (chemical or surgical) androgen deprivation with serum testosterone \< 50 ng/dL (\< 1.7 nM)
* Has received prior treatment with poly(ADP-ribose) polymerase (PARP) inhibitor, if appropriate, or deemed ineligible to receive treatment by the Investigator, or has refused PARP inhibitor treatment
* Has received prior treatment with at least 1 line of ARPi
* Have disease measurable per Prostate Cancer Working Group 4 (PCWG4) criteria, with or without measurable disease by RECIST 1.1
* Be able to provide a tumor biopsy for biomarker analysis during the Screening period
* Have adequate organ function

Exclusion Criteria:

* • Have received prior chemotherapy, definitive radiation, or biological cancer therapy within 21 days before the first dose of study treatment or have any AEs that have failed to recover to baseline

  * Have received prior therapy with a GSPT1 degrader that was discontinued due to an AE
  * Have received prior auto-HCT and have not fully recovered from effects of the last transplant
  * Have received allogeneic hematopoietic stem cell transplantation within past 6 months and/or have symptoms of graft-versus-host disease
  * Current use of chronic systemic steroid therapy in excess of replacement doses
  * Have clinically active central nervous system involvement and/or carcinomatous meningitis
  * Have a confirmed history of (noninfectious) pneumonitis that required steroids
  * Clinically significant cardiac disease

Conditions5

Interventions2

Locations14 sites

Find trials near these locations

Related trials

• Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer — Institute of Cancer Research, United Kingdom
• Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer — The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
• ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer — Karolinska Institutet
• Surgical Treatment With or Without Apalutamide in Subjects With High Risk Prostate Cancer Who Are Candidates for Radical Prostatectomy and Staged as Oligometastatic With PSMA-PET — Marco Oderda
• The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs — Helsinki University Central Hospital
• AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01) — AstraZeneca
• Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response — Canadian Cancer Trials Group
• Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging — ECOG-ACRIN Cancer Research Group

Browse More Trials